Prospective study of genital human papillomaviruses and nonmelanoma skin cancer

International Journal of Cancer

Volumn 133, Issue 8, 2013, Pages 1840-1845

  Andersson, Kristin ^a   Luostarinen, Tapio ^b   Strand, Anna Söderlund ^a   Langseth, Hilde ^c   Gislefoss, Randi E ^c   Forslund, Ola ^a   Pawlita, Michael ^d   Waterboer, Tim ^d   Dillner, Joakim ^a,e  

^a LUND UNIVERSITY   (Sweden)

^b FINNISH CANCER REGISTRY   (Finland)

^c CANCER REGISTRY OF NORWAY   (Norway)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

basal cell carcinoma; human papillomavirus; real time PCR; serology; squamous cell carcinoma

Indexed keywords

VIRUS ANTIBODY; VIRUS DNA;

ARTICLE; BASAL CELL CARCINOMA; BLOOD DONOR; BLOOD SAMPLING; CANCER REGISTRY; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NON MELANOMA SKIN CANCER; NORWAY; PERINEUM; PRIORITY JOURNAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; SKIN CARCINOMA; SWEDEN;

BASAL CELL CARCINOMA; HUMAN PAPILLOMAVIRUS; REAL-TIME PCR; SEROLOGY; SQUAMOUS CELL CARCINOMA;

AGED; ANTIBODIES, VIRAL; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; DNA, VIRAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MALE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; REGISTRIES; REPRODUCTIVE TRACT INFECTIONS; SKIN NEOPLASMS;

EID: 84881542019     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28188     Document Type: Article

References (32)

1. de Villiers E-M, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004; 324: 17-27.
2. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-65.
3. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens. Part B. Biological agents. Lancet Oncol 2009; 10: 321-2.
4. Dillner J,. The serological response to papillomaviruses. Semin Cancer Biol 1999; 9: 423-30.
5. Schiller JT, Castellsague X, Villa LL, et al. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008; 26 (Suppl 10): K53-K61.
6. Feltkamp MC, Broer R, di Summa FM, et al. Seroreactivity to epidermodysplasia verruciformis-related human papillomavirus types is associated with nonmelanoma skin cancer. Cancer Res 2003; 63: 2695-700.
7. Andersson K, Waterboer T, Kirnbauer R, et al. Seroreactivity to cutaneous human papillomaviruses among patients with nonmelanoma skin cancer or benign skin lesions. Cancer Epidemiol Biomarkers Prev 2008; 17: 189-95.
8. Casabonne D, Michael KM, Waterboer T, et al. A prospective pilot study of antibodies against human papillomaviruses and cutaneous squamous cell carcinoma nested in the Oxford component of the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2007; 121: 1862-8.
9. Paradisi A, Waterboer T, Sampogna F, et al. Seropositivity for human papillomavirus and incidence of subsequent squamous cell and basal cell carcinomas of the skin in patients with a previous nonmelanoma skin cancer. Br J Dermatol 2011; 165: 782-91.
10. Casabonne D, Lally A, Mitchell L, et al. A case-control study of cutaneous squamous cell carcinoma among Caucasian organ transplant recipients: the role of antibodies against human papillomavirus and other risk factors. Int J Cancer 2009; 125: 1935-45.
11. Antonsson A, Erfurt C, Hazard H, et al. Prevalence and type spectrum of human papillomaviruses in healthy skin samples collected in three continents. J Gen Virol 2003; 84: 1881-6.
12. Forslund O, Iftner T, Andersson K, et al. Cutaneous human papillomaviruses found in sun-exposed skin: beta-papillomavirus species 2 predominates in squamous cell carcinoma. J Infect Dis 2007; 196: 876-83.
13. Asgari MM, Kiviat NB, Critchlow CW, et al. Detection of human papillomavirus DNA in cutaneous squamous cell carcinoma among immunocompetent individuals. J Invest Dermatol 2008; 128: 1409-17.
14. Iftner A, Klug SJ, Garbe C, et al. The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factors. Cancer Res 2003; 63: 7515-19.
15. Harwood CA, Surentheran T, McGregor JM, et al. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 2000; 61: 289-97.
16. Reuschenbach M, Tran T, Faulstich F, et al. High-risk human papillomavirus in non-melanoma skin lesions from renal allograft recipients and immunocompetent patients. Br J Cancer 2011; 104: 1334-41.
17. Ruer JB, Pepin L, Gheit T, et al. Detection of alpha- and beta-human papillomavirus (HPV) in cutaneous melanoma: a matched and controlled study using specific multiplex PCR combined with DNA microarray primer extension. Exp Dermatol 2009; 18: 857-62.
18. La Placa M, Ambretti S, Bonvicini F, et al. Presence of high-risk mucosal human papillomavirus genotypes in primary melanoma and in acquired dysplastic melanocytic naevi. Br J Dermatol 2005; 152: 909-14.
19. Forslund O, Nordin P, Hansson BG,. Mucosal human papillomavirus types in squamous cell carcinomas of the uterine cervix and subsequently on fingers. Br J Dermatol 2000; 142: 1148-53.
20. Nakajima H, Teraishi M, Tarutani M, et al. High prevalence of coinfection with mucosal high-risk type HPV (HR-HPV) and cutaneous HR-HPV in Bowen's disease in the fingers. J Dermatol Sci 2010; 60: 50-2.
21. Hayashi S, Hatamochi A, Soutome A, et al. A case of epidermodysplasia verruciformis (EV) with human papillomavirus 16 (HPV16) DNA detected in the skin lesions: can HPV16 infect patients with EV? Int J Dermatol 2011; 50: 1168-70.
22. Lehtinen M, Dillner J,. Preventive human papillomavirus vaccination. Sex Transm Infect 2002; 78: 4-6.
23. Hughes DS, Powell N, Fiander AN,. Will vaccination against human papillomavirus prevent eye disease? A review of the evidence. Br J Ophthalmol 2008; 92: 460-5.
24. Nindl I, Meyer T, Schmook T, et al. Human papillomavirus and overexpression of P16INK4a in nonmelanoma skin cancer. Dermatol Surg 2004; 30: 409-14.
25. Andersson K, Michael KM, Luostarinen T, et al. Prospective study of human papillomavirus seropositivity and risk of nonmelanoma skin cancer. Am J Epidemiol 2012; 175: 685-95.
26. Clifford GM, Shin HR, Oh JK, et al. Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev 2007; 16: 1874-9.
27. Waterboer T, Sehr P, Michael KM, et al. Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem 2005; 51: 1845-53.
28. Sehr P, Zumbach K, Pawlita M,. A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. J Immunol Methods 2001; 253: 153-62.
29. Waterboer T, Sehr P, Pawlita M,. Suppression of non-specific binding in serological Luminex assays. J Immunol Methods 2006; 309: 200-4.
30. Arnheim Dahlstrom L, Andersson K, Luostarinen T, et al. Prospective seroepidemiologic study of human papillomavirus and other risk factors in cervical cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 2541-50.
31. Saiki RK, Scharf S, Faloona F, et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 1985; 230: 1350-4.
32. Moberg M, Gustavsson I, Gyllensten U,. Real-time PCR-based system for simultaneous quantification of human papillomavirus types associated with high risk of cervical cancer. J Clin Microbiol 2003; 41: 3221-8.